TANDEM DIABETES CARE INC·4

May 22, 4:04 PM ET

Cha Myoungil 4

4 · TANDEM DIABETES CARE INC · Filed May 22, 2026

Research Summary

AI-generated summary of this filing

Updated

Tandem Diabetes (TNDM) Director Cha Myoungil Receives RSU Award & Vesting

What Happened

  • Director Cha Myoungil received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026 (reported as an award/derivative acquisition). The filing also reports that 8,759 RSUs vested/converted into shares on May 21, 2026 (reported as a derivative exercise/conversion), with a corresponding reported disposition of the same 8,759 shares on May 21, 2026. All transactions are reported at $0.00 per share (typical for RSU vesting/conversion).

Key Details

  • Transaction dates: May 20, 2026 (grant of 10,220 RSUs); May 21, 2026 (conversion/vesting of 8,759 RSUs and a matching disposition).
  • Prices: $0.00 per share for the RSU award and the conversion entries (RSUs convert to shares without an exercise price).
  • Shares owned after transaction: Not disclosed in this Form 4.
  • Footnotes of note:
    • F1: Each RSU represents a contingent right to receive one share or cash in lieu, per the 2023 Long-Term Incentive Plan.
    • F2: The 10,220 RSUs granted May 20, 2026 will vest on the one‑year anniversary, subject to plan terms.
    • F3: The 8,759 RSUs referenced were a prior grant (May 21, 2025) that vested and converted on the one‑year anniversary (May 21, 2026).
  • Filing timeliness: Form filed May 22, 2026; no late filing flag indicated.

Context

  • These entries relate to RSU awards and the one‑year vesting/settlement of previously granted RSUs — a routine form of equity compensation for directors and employees. The filing shows both conversion/acquisition of shares from vested RSUs and a simultaneous disposition of the same number of shares; filings sometimes show dispositions for tax withholding or net settlement, but this Form 4 does not specify the reason. This is not an open‑market buy or sell that directly signals a trading decision.

Insider Transaction Report

Form 4
Period: 2026-05-20
Cha Myoungil
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2026-05-21+8,75922,458 total
  • Award

    Restricted Stock Unit

    [F1][F2]
    2026-05-20+10,22010,220 total
    Common Stock (10,220 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    [F1][F3]
    2026-05-218,7590 total
    Common Stock (8,759 underlying)
Footnotes (3)
  • [F1]Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
  • [F2]Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.
  • [F3]On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.
Signature
/s/ Jerilyn Laskie, Attorney-in-Fact for Myoungil Cha|2026-05-22

Documents

3 files